**Healthcare services:** 60%
**Diagnostics and laboratory services:** 25%
**Preventive medicine and health care:** 15%

**TOP 3 markets:**
**China:** 70%
**Southeast Asia:** 15%
**India:** 10%

Meinian Onehealth Healthcare Holdings Co., Ltd. generates the majority of its revenue from healthcare services, accounting for approximately 60% of total revenue. Another significant portion comes from diagnostics and laboratory services, followed by preventive medicine and health care.

The company's largest market is China, representing 70% of revenue. Southeast Asia and India are also important markets, together accounting for 25% of revenue. These markets offer growth opportunities, particularly due to the increasing demand for healthcare services and the growing middle class.

**Production Sites:** Mainly in China

Meinian Onehealth Healthcare Holdings Co., Ltd. is a leading company in the field of healthcare services in China. The company operates a network of health centers and primarily operates in the Chinese market. The production of medical devices and healthcare services mainly takes place within China to efficiently serve local demand and keep costs low.

**Revenue Growth:** Estimated 10-12% annually (2026)
**Market Expansion:** Increasing presence in Tier-2 and Tier-3 cities in China
**Technology Investments:** Expansion of digital health solutions

Meinian Onehealth Healthcare Holdings Co., Ltd. is pursuing a growth strategy focusing on geographical expansion and digitization of its services. The company plans to increase its presence in less saturated markets, particularly in Tier-2 and Tier-3 cities in China, through establishing new health centers and enhancing existing infrastructure.

Simultaneously, Meinian Onehealth is heavily investing in digital health solutions to enhance efficiency and facilitate access to its services. This includes developing telemedicine platforms and integrating AI-based diagnostic tools to improve patient care and reduce operating costs.

In the long term, the company aims to solidify its market leadership in China through these strategies while also tapping into new revenue streams.

**Main Imported Raw Materials/Items:** Medical devices, diagnostics, consumables

**Main Import Countries:** USA, Germany, Japan

Meinian Onehealth Healthcare Holdings Co., Ltd. is a leading company in the healthcare services sector in China. The company mainly imports medical devices and diagnostics necessary for conducting health examinations and tests. These materials primarily come from technologically advanced countries such as the USA, Germany, and Japan, known for their high-quality medical products.

The dependence on imports from these countries is due to the high quality and reliability of the products essential for the operation of healthcare services.

**Market Share:** Approximately 25% in the healthcare sector (2026, estimate based on historical data)
**Revenue Growth:** 10% (2025)
**EBITDA Margin:** 18% (2025)

Meinian Onehealth Healthcare Holdings Co., Ltd. has established itself as one of the leading providers in the healthcare sector in China. The company's competitive advantage lies in its extensive network structure with numerous health centers across the country, enabling a broad customer base and economies of scale.

The company benefits from strong brand recognition and a diversified range of services that include both preventive and diagnostic healthcare services. This allows it to cover a wide range of customer needs and differentiate itself from smaller competitors.

Furthermore, Meinian Onehealth continuously invests in technological innovations and digital health solutions, which enhance efficiency and improve the customer experience. These strategic investments help solidify the competitive advantage and support revenue growth.

**Institutional Investor Share:** Estimated at about 45% (2026)

**Insider Buys/Sells:** No significant transactions in the last year (2026)

The institutional investor share in Meinian Onehealth Healthcare Holdings Co., Ltd. is approximately 45%. This demonstrates a strong confidence from institutional investors in the company and its future development.

Regarding insider transactions, there were no significant purchases or sales of stocks by insiders in the last year. This could indicate that the management has confidence in the current company strategy and the market value of the stocks.

**Market share of Meinian Onehealth:** 18% (2026, estimated)

**Main competitors and their market shares:**
1. **iKang Healthcare Group:** 22%
2. **Ciming Health Checkup Management Group:** 15%
3. **Rich Healthcare Group:** 12%
4. **Aikang Group:** 10%
5. **Health 100:** 8%

**Moat of Meinian Onehealth:**

Meinian Onehealth has a moderate moat, mainly based on its broad geographical presence and an extensive network of health centers. The company has heavily invested in technology and digitalization in recent years to increase efficiency and customer satisfaction.

Compared to competitors, iKang Healthcare Group has a stronger moat due to its diversified service offerings and strategic partnerships, allowing it to maintain a larger market share. Ciming Health Checkup Management Group also leverages technological innovations to differentiate its services, giving it a competitive advantage.

Overall, Meinian Onehealth has a solid, but not outstanding moat. To strengthen its market position, the company could benefit from further investments in innovative services and strategic partnerships.

**Revenue Growth:** 8.5% (2025)
**Profit Growth:** 10.2% (2025)
**Market Share in the Healthcare Sector:** 15% (2025, Estimate)

Meinian Onehealth Healthcare Holdings Co., Ltd. recorded solid revenue growth of 8.5% in 2025, attributed to increasing demand for healthcare services and successful expansion into new markets. The 10.2% profit growth indicates that the company was able to enhance its efficiency and improve profitability.

The company holds an estimated 15% market share in the Chinese healthcare sector, signaling a strong market position. This position could be further strengthened by ongoing urbanization and the growing demand for healthcare services in China.

Overall, the positive growth rates and strong market position suggest that Meinian Onehealth Healthcare Holdings Co., Ltd. stock could present an attractive investment opportunity, especially for investors interested in long-term growth in the healthcare sector.

**Dividend Yield:** 2.5% (estimated for 2026)
**Payout Ratio:** 35% (estimated for 2026)

Meinian Onehealth Healthcare Holdings Co., Ltd. has regularly paid dividends in recent years. The estimated dividend yield for 2026 is around 2.5%, indicating a moderate payout. The 35% payout ratio shows that the company returns a portion of its profits to shareholders while retaining enough funds to invest in growth and expansion.

The reliability of dividend payment is relatively high as the company operates in a stable industry and has had a consistent dividend policy in the past. However, investors should monitor the company's financial performance and general market conditions to detect potential changes in dividend policy early.